论文部分内容阅读
目的：检测急性脑梗死（ACI）患者血清中超敏C反应蛋白（hs-CRP）的水平，并探讨其临床意义。方法收集80例ACI患者空腹外周血标本，以后循环缺血（PCI）和非脑血管病（NCD）患者为对照，采用免疫比浊法，通过全自动生化分析仪测定血清中hs-CRP的水平，同时检测血清中葡萄糖（Glu）、总胆固醇（TC）、高密度脂蛋白（HDL-C）和低密度脂蛋白（LDL-C）等指标。结果(1)与PCI组（3.56±3.89 mg/L）和NCD组（2.65±3.02 mg/L）比较，ACI患者血清中hs-CRP水平（7.35±5.93 mg/L）显著升高（P＜0.01）；ACI患者血清Glu水平也显著高于对照组，但与hs-CRP水平无明显相关性；在ACI患者和对照组之间，TC、HDL-C、LDL-C的含量差异无统计学意义。(2)ACI患者hs-CRP水平与梗死部位无关；但是与神经功能缺损显著相关（r=0.627，P＜0.001）；在不同梗死体积的ACI患者之间，hs-CRP水平差异也具有统计学意义（P＜0.05）。(3)抗血小板联合调脂治疗能够显著降低ACI患者hs-CRP水平（P=0.034）。结论ACI患者血清中hs-CRP水平显著升高，与梗死体积、神经功能缺损和药物治疗显著相关，提示hs-CRP作为ACI炎症标志的潜在应用价值。“,”Objective To explore the clinical signiifcance of high-sensitivity C-reactive protein (hs-CRP) in patients with acute cerebral infarction (ACI) by detecting its levels in serum samples. Methods Peripheral blood samples of 80 ACI patients were collected in this study. 31 patients with posterior circulation ischemia (PCI) and 49 patients with non-cerebrovascular disease (NCD) served as controls. Serum levels of hs-CRP, glucose (Glu), to-tal cholesterol (TC), high density lipoprotein-cholesterol (HDL-C) and low density lipoprotein-cholesterol (LDL-C) were detected by full-automatic biochemical analyzer. Results (1)Levels of hs-CRP in ACI patients (7.35±5.93 mg/L) were higher than those in PCI (3.56±3.89 mg/L) and NCD (2.65±3.02 mg/L) patients (both P<0.01). Glu levels were elevated in ACI patients as compared with those in controls, but not correlated to hs-CRP levels. Lev-els of TC, HDL-C and LDL-C demonstrated no statistical signiifcance between ACI patients and controls. (2)hs-CRP levels showed no signiifcant difference between different infarct locations. However, its levels were closely correlated to brain infarct volumes and neurological deifcits (all P<0.05). (3)Combined therapy with aspirin and atorvastatin signiifcantly reduced hs-CRP levels as compared to aspirin monotherapy (P=0.034). Conclusion In ACI patients, hs-CRP levels were increased and associated with the severity, outcome and therapy of the disease, suggesting that hs-CRP may be a promising biomarker for diagnosis and prognosis in ACI.